Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IKT
DateTimeSourceHeadlineSymbolCompany
06/12/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IKTInhibikase Therapeutics Inc
05/12/202421:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
05/12/202421:47Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IKTInhibikase Therapeutics Inc
03/12/202411:24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
18/11/202421:49Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IKTInhibikase Therapeutics Inc
18/11/202421:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
14/11/202413:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IKTInhibikase Therapeutics Inc
08/11/202421:07Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
28/10/202421:26Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
28/10/202420:00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
25/10/202421:52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
25/10/202421:50Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
23/10/202423:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
23/10/202423:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
23/10/202423:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
23/10/202423:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
23/10/202423:38Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
23/10/202423:35Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
17/10/202423:00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
17/10/202420:05Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IKTInhibikase Therapeutics Inc
10/10/202421:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
09/10/202412:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
14/08/202420:25GlobeNewswire Inc.Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
14/08/202420:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IKTInhibikase Therapeutics Inc
07/08/202412:00GlobeNewswire Inc.Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024NASDAQ:IKTInhibikase Therapeutics Inc
18/07/202421:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
18/07/202421:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IKTInhibikase Therapeutics Inc
18/06/202421:27Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:IKTInhibikase Therapeutics Inc
17/06/202412:05GlobeNewswire Inc.Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s DiseaseNASDAQ:IKTInhibikase Therapeutics Inc
10/06/202420:20Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IKTInhibikase Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:IKT